vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Ares Commercial Real Estate Corp (ACRE). Click either name above to swap in a different company.
Ares Commercial Real Estate Corp is the larger business by last-quarter revenue ($13.2M vs $10.7M, roughly 1.2× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -29.2%, a 52.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -24.5%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -15.9%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
ABUS vs ACRE — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $13.2M |
| Net Profit | $2.5M | $-3.9M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -29.2% |
| Net Margin | 23.5% | -29.2% |
| Revenue YoY | 522.2% | -24.5% |
| Net Profit YoY | 112.7% | 63.8% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.2M | ||
| Q3 25 | — | $14.1M | ||
| Q2 25 | $10.7M | $12.6M | ||
| Q1 25 | — | $14.9M | ||
| Q4 24 | — | $17.5M | ||
| Q3 24 | — | $16.7M | ||
| Q2 24 | — | $16.8M | ||
| Q1 24 | — | $18.7M |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | $2.5M | $-11.0M | ||
| Q1 25 | — | $9.3M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | — | $-5.9M | ||
| Q2 24 | — | $-6.1M | ||
| Q1 24 | — | $-12.3M |
| Q4 25 | — | -29.2% | ||
| Q3 25 | — | 33.0% | ||
| Q2 25 | 13.9% | -87.8% | ||
| Q1 25 | — | 64.4% | ||
| Q4 24 | — | -61.0% | ||
| Q3 24 | — | -35.3% | ||
| Q2 24 | — | -36.5% | ||
| Q1 24 | — | -65.9% |
| Q4 25 | — | -29.2% | ||
| Q3 25 | — | 33.0% | ||
| Q2 25 | 23.5% | -87.8% | ||
| Q1 25 | — | 62.5% | ||
| Q4 24 | — | -60.9% | ||
| Q3 24 | — | -35.3% | ||
| Q2 24 | — | -36.5% | ||
| Q1 24 | — | -65.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $29.3M |
| Total DebtLower is stronger | $0 | $948.2M |
| Stockholders' EquityBook value | $83.0M | $509.6M |
| Total Assets | $103.3M | $1.6B |
| Debt / EquityLower = less leverage | 0.00× | 1.86× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $29.3M | ||
| Q3 25 | — | $84.9M | ||
| Q2 25 | $37.4M | $90.0M | ||
| Q1 25 | — | $125.5M | ||
| Q4 24 | — | $63.8M | ||
| Q3 24 | — | $68.9M | ||
| Q2 24 | — | $70.6M | ||
| Q1 24 | — | $99.5M |
| Q4 25 | — | $948.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $718.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $509.6M | ||
| Q3 25 | — | $521.0M | ||
| Q2 25 | $83.0M | $523.7M | ||
| Q1 25 | — | $542.1M | ||
| Q4 24 | — | $540.1M | ||
| Q3 24 | — | $563.8M | ||
| Q2 24 | — | $582.3M | ||
| Q1 24 | — | $601.1M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $103.3M | $1.4B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.1B |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $21.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.4M | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | $-15.7M | $4.9M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $35.5M | ||
| Q3 24 | — | $8.4M | ||
| Q2 24 | — | $8.7M | ||
| Q1 24 | — | $11.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.82× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
